Zacks Investment Research lowered shares of Innophos (NASDAQ:IPHS) from a hold rating to a strong sell rating in a report published on Thursday.

According to Zacks, “Innophos, Inc., is one of the leading North American manufacturers of specialty phosphates, serving a diverse range of customers across multiple applications, geographies and channels. Innophos offers a broad suite of products used in a wide variety of food and beverage, consumer products, pharmaceutical and industrial applications. Innophos’ market-leading positions derive from its experience and dedication to customer service and innovation. “

A number of other research firms also recently weighed in on IPHS. BidaskClub downgraded Innophos from a buy rating to a hold rating in a research note on Wednesday, July 25th. ValuEngine downgraded Innophos from a hold rating to a sell rating in a research note on Friday, October 12th. Finally, TheStreet downgraded Innophos from a b- rating to a c+ rating in a research note on Thursday, August 23rd. Three investment analysts have rated the stock with a sell rating and one has given a hold rating to the stock. Innophos has an average rating of Sell and an average price target of $51.00.

IPHS stock opened at $30.68 on Thursday. Innophos has a fifty-two week low of $29.18 and a fifty-two week high of $50.40. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.34 and a current ratio of 2.75. The company has a market cap of $601.57 million, a P/E ratio of 12.47 and a beta of 0.70.

Innophos (NASDAQ:IPHS) last posted its quarterly earnings results on Monday, July 30th. The specialty chemicals company reported $0.55 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.10). Innophos had a return on equity of 14.28% and a net margin of 2.21%. The firm had revenue of $206.73 million for the quarter, compared to analyst estimates of $213.40 million. During the same period last year, the company posted $0.57 earnings per share. The firm’s quarterly revenue was up 15.4% compared to the same quarter last year. On average, equities research analysts forecast that Innophos will post 2.35 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. bought a new stake in Innophos during the 2nd quarter worth approximately $144,000. Raymond James & Associates bought a new stake in Innophos during the 2nd quarter worth approximately $209,000. Ifrah Financial Services Inc. bought a new stake in Innophos during the 2nd quarter worth approximately $210,000. Dynamic Technology Lab Private Ltd bought a new stake in Innophos during the 2nd quarter worth approximately $217,000. Finally, Alps Advisors Inc. bought a new stake in Innophos during the 2nd quarter worth approximately $213,000. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Innophos Company Profile

Innophos Holdings, Inc, together with its subsidiaries, produces specialty ingredients with applications in food, health, nutrition, and industrial markets. It operates through three segments: Food, Health and Nutrition; Industrial Specialties; and Other. The company's specialty ingredients include specialty phosphate salts and specialty phosphoric acids, as well as other mineral, enzyme, and botanical based specialty ingredients that are used as flavor enhancers in beverages; electrolytes in sports drinks; texture modifiers in cheeses; leavening agents in baked goods; calcium and phosphorus fortification in food and beverages; moisture and color retention in seafood, poultry, and meat; excipients in vitamins, minerals, nutritional supplements, and pharmaceuticals; and abrasives in toothpaste.

See Also: Do You Need a Fiduciary?

Get a free copy of the Zacks research report on Innophos (IPHS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innophos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innophos and related companies with MarketBeat.com's FREE daily email newsletter.